Herpes Zoster (HZ) is a blistering, painful and disabling cutaneous rash that can occur in any type of patient at any age. It is caused by reactivation of the Varicella Zoster Virus (VZV). Autoimmune inflammatory rheumatic diseases (AIIRDs) are associated with an increased risk of infections due to use of corticosteroids, comorbidities, the immunosuppressive effect of AIIRDs themselves and of the drugs used to treat them. In light of the clinical and psychological effects of HZ and its complications in affected patients, it is essential to carry out a prevention strategy by implementing vaccination programs in appropriate age and high-risk groups, given also the availability of the new recombinant adjuvanted anti-Herpes Zoster (RZV) vaccine in Italy. The College of Italian Rheumatology think it is useful to share some scientific data on the epidemiological and clinical impact of HZ in patients with AIIRDs and on the current national vaccine availability.